13/02/2018 15:30:00

Medovex Corporation Presents Initial Data on the DenerveX® System During NSpine 2nd Platinum Course in Arosa, Switzerland

ATLANTA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB:MDVX) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that the Company participated at the NSpine Platinum Small Group Educational Event in Arosa, Switzerland, held January 29th through February 3rd, 2018.

Medovex medical advisory board member Vik Kapoor MD, from Manchester, U.K. presented on two separate days at the N-Spine Platinum Small Group Educational Event. Dr. Kapoor presented initial data on his first 20 cases using the DenerveX System, which he considers very positive. The presentation was well received by approximately 50 European neuro, spinal, and orthopedic surgeons. Attending surgeons were granted 30 European CME credits (6 ECMEC® per day) by the European Accreditation Council for Continuing Medical Education (EACCME). 

A third day marketing presentation focused on the DenerveX System including discussion related to reimbursement opportunities specific to individual countries, leading to expressed interest from many attendees to start performing DenerveX cases in their respective countries.

In an effort to enhance the value of the meeting, the third day of the event consisted of novel technologies identified by NSpine as improving the field of spine care. The Medovex team was pleased to have been selected.

The value of the Arosa meeting lies in its educational content – to gain a greater understanding of current trends and decision making in spinal surgery – and in the networking with senior decision makers in the world of spinal surgery.

Manfred Sablowski, Medovex Senior Vice President of Global Sales & Marketing stated, “We are pleased to have been selected for participation at The NSpine Platinum Small Group Educational Event. The professional networks built through these events are as valuable as the educational content itself. During this master’s course, Medovex had the privilege of meeting many of the world’s preeminent surgeons who we continue to draw on for advice in managing unusually complex cases.”

Sablowski continued, “Events like these are important milestones for Medovex, as well as a key inflection point gaining us leverage for our Company’s growth strategy focused in Europe, South America, and Australia. Importantly, it provides potential future customers the opportunity to experience firsthand the intuitive DenerveX System.”

Please also follow us on Facebook at https://www.facebook.com/medovex/.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.

Safe Harbor Statement                                                     

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

 

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker mine analyse af Pandoras forretnings..
82
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 Feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
30
17 Feb
MAERSK-B
Jeg er i mit vemodige hjørne i dag, for det er den første dag i over 25 år, hvor jeg ikke kan kalde ..
20
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
20
15 Feb
OMXC20
Kære alle. Jeg har flere gange tilbudt at svare på investeringsspørgsmål for at bidrage til at så ma..
20
17 Feb
E:QEC
Med fare for en gentagelse, så vil jeg alligevel melde at Canada er i fuld gang med at omstille sig ..
18
17 Feb
NOVO-B
@alpenyt Tror bare jeg vil kalde dig for Wiki(pedia) fra nu af :) Du burde skrive en artikel i kvart..
17
16 Feb
NOVO-B
Jeg deltager, modsat dig, med argumenter og fakta, du er blot personfnidrer, fordi du ikke kan forst..
15

Investec Bank plc : Form 8.5 (EPT/RI) - Melrose Industries Plc.

21/02/2018 10:28:16
  FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Alliance Trust PLC : Transaction in Own Shares

21/02/2018 07:00:17
21 February 2018  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 20 February 2018 the Company purchased for cancellation 100,000 ordinary shares of 2.5p each at a price of 726.2368p per share.  Therefore, the total number of voting rights in the Company is now 343,820,589.    The above figure (343,820,589) may be used by sha..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

20/02/2018 15:25:09
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bermuda Principles event merges science and business
2
Pöyry provides lenders technical advisory services as Cirebon 2 power plant project in Indonesia achieves financial close
3
UPDATE:  Youngevity Completes Acquisition of Nature Direct
4
TransAtlantic Petroleum Provides Investor Presentations and Marketing Process Update
5
Value Exchange International, Inc. Subsidiary Signs Point of Sale Systems and Support Services Contract with the Largest Health and Beauty Retailer in China

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 February 2018 13:04:01
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180219.1 - EUROWEB1 - 2018-02-21 14:04:01 - 2018-02-21 13:04:01 - 1000 - Website: OKAY